Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives
- PMID: 10359672
- PMCID: PMC1220319
Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives
Abstract
Cytochrome P450 3A4 (CYP3A4) plays a prominent role in the metabolism of a vast array of drugs and xenobiotics and exhibits broad substrate specificities. Most cytochrome P450-mediated reactions follow simple Michaelis-Menten kinetics. These parameters are widely accepted to predict pharmacokinetic and pharmacodynamic consequences in vivo caused by exposure to one or multiple drugs. However, CYP3A4 in many cases exhibits allosteric (sigmoidal) characteristics that make the Michaelis constants difficult to estimate. In the present study, diazepam, temazepam and nordiazepam were employed as substrates of CYP3A4 to propose a kinetic model. The model hypothesized that CYP3A4 contains two substrate-binding sites in a single active site that are both distinct and co-operative, and the resulting velocity equation had a good fit with the sigmoidal kinetic observations. Therefore, four pairs of the kinetic estimates (KS1, kalpha, KS2, kbeta, KS3, kdelta, KS4 and kgamma) were resolved to interpret the features of binding affinity and catalytic ability of CYP3A4. Dissociation constants KS1 and KS2 for two single-substrate-bound enzyme molecules (SE and ES) were 3-50-fold greater than KS3 and KS4 for a two-substrate-bound enzyme (SES), while respective rate constants kdelta and kgamma were 3-218-fold greater than kalpha and kbeta, implying that access and binding of the first molecule to either site in an active pocket of CYP3A4 can enhance the binding affinity and reaction rate of the vacant site for the second substrate. Thus our results provide some new insights into the co-operative binding of two substrates in the inner portions of an allosteric CYP3A4 active site.
Similar articles
-
The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4.Toxicol Appl Pharmacol. 1996 Dec;141(2):595-606. doi: 10.1006/taap.1996.0326. Toxicol Appl Pharmacol. 1996. PMID: 8975785
-
Elucidation of distinct ligand binding sites for cytochrome P450 3A4.Biochemistry. 2000 May 23;39(20):5929-39. doi: 10.1021/bi992765t. Biochemistry. 2000. PMID: 10821664
-
Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling.Arch Biochem Biophys. 2003 Jan 1;409(1):92-101. doi: 10.1016/s0003-9861(02)00484-8. Arch Biochem Biophys. 2003. PMID: 12464248
-
Modelling atypical CYP3A4 kinetics: principles and pragmatism.Arch Biochem Biophys. 2005 Jan 15;433(2):351-60. doi: 10.1016/j.abb.2004.09.010. Arch Biochem Biophys. 2005. PMID: 15581591 Review.
-
Differential behavior of the sub-sites of cytochrome 450 active site in binding of substrates, and products (implications for coupling/uncoupling).Biochim Biophys Acta. 2007 Mar;1770(3):360-75. doi: 10.1016/j.bbagen.2006.09.018. Epub 2006 Oct 5. Biochim Biophys Acta. 2007. PMID: 17134838 Review.
Cited by
-
Numerical Methods for Modeling Enzyme Kinetics.Methods Mol Biol. 2021;2342:147-168. doi: 10.1007/978-1-0716-1554-6_6. Methods Mol Biol. 2021. PMID: 34272694
-
Intrinsic noise analyzer: a software package for the exploration of stochastic biochemical kinetics using the system size expansion.PLoS One. 2012;7(6):e38518. doi: 10.1371/journal.pone.0038518. Epub 2012 Jun 12. PLoS One. 2012. PMID: 22723865 Free PMC article.
-
Cooperative properties of cytochromes P450.Pharmacol Ther. 2009 Nov;124(2):151-67. doi: 10.1016/j.pharmthera.2009.05.011. Epub 2009 Jun 23. Pharmacol Ther. 2009. PMID: 19555717 Free PMC article. Review.
-
Role of P-glycoprotein in pharmacokinetics: clinical implications.Clin Pharmacokinet. 2003;42(1):59-98. doi: 10.2165/00003088-200342010-00003. Clin Pharmacokinet. 2003. PMID: 12489979 Review.
-
Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.Br J Clin Pharmacol. 2018 Mar;84(3):501-509. doi: 10.1111/bcp.13478. Epub 2018 Jan 10. Br J Clin Pharmacol. 2018. PMID: 29178272 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources